Literature DB >> 24510389

Association between XPD Lys751Gln polymorphism and bladder cancer susceptibility: an updated and cumulative meta-analysis based on 6,836 cases and 8,251 controls.

Sheng Li1, Xian Tao Zeng, Xiao Lan Ruan, Tong Zu Liu, Xing Huan Wang.   

Abstract

The association between xeroderma pigmentosum group D (XPD) Lys751Gln polymorphism and bladder cancer (BC) susceptibility was investigated by two meta-analyses, however, their results were contrary. We conjecture the reason might be the sample size, thus we performed this updated and cumulative meta-analysis using the Comprehensive Meta-Analysis software. We searched PubMed up to August 25th, 2013 and yielded 20 published articles with 21 case-control trails including 6,836 BC patients and 8,251 controls. The meta-analysis results showed that XPD Lys751Gln polymorphism was borderline significantly associated with BC susceptibility for overall population [Gln vs. Lys: OR 1.07, 95% CI 1.01-1.12, P = 0.01; Gln/Gln vs. Lys/Lys: OR 1.15, 95% CI 1.03-1.29, P = 0.01; Gln/Gln vs. (Lys/Gln + Lys/Lys): OR 1.13, 95% CI 1.02-1.26, P = 0.02]. The cumulative meta-analysis according to the publication year showed the CI became increasingly narrower and tended to have statistical significance for the studies incessantly accumulated. In the subgroup analysis according to ethnicity, there was a significant association in Asian population and no association in Caucasian population. There was no publication bias detected. However, due to the limitations and cumulative analysis result of this meta-analysis, more well-designed and larger studies with risk factors adjusted are suggested to be performed to obtain a conclusive result on this topic.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24510389     DOI: 10.1007/s11033-014-3226-2

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  37 in total

1.  Quantifying heterogeneity in a meta-analysis.

Authors:  Julian P T Higgins; Simon G Thompson
Journal:  Stat Med       Date:  2002-06-15       Impact factor: 2.373

2.  DNA repair polymorphisms and cancer risk in non-smokers in a cohort study.

Authors:  G Matullo; A M Dunning; S Guarrera; C Baynes; S Polidoro; S Garte; H Autrup; C Malaveille; M Peluso; L Airoldi; F Veglia; E Gormally; G Hoek; M Krzyzanowski; K Overvad; O Raaschou-Nielsen; F Clavel-Chapelon; J Linseisen; H Boeing; A Trichopoulou; D Palli; V Krogh; R Tumino; S Panico; H B Bueno-De-Mesquita; P H Peeters; E Lund; G Pera; C Martinez; M Dorronsoro; A Barricarte; M J Tormo; J R Quiros; N E Day; T J Key; R Saracci; R Kaaks; E Riboli; P Vineis
Journal:  Carcinogenesis       Date:  2005-11-23       Impact factor: 4.944

3.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Authors:  David Moher; Alessandro Liberati; Jennifer Tetzlaff; Douglas G Altman
Journal:  Int J Surg       Date:  2010-02-18       Impact factor: 6.071

Review 4.  Is there evidence of involvement of DNA repair polymorphisms in human cancer?

Authors:  Fulvio Ricceri; Giuseppe Matullo; Paolo Vineis
Journal:  Mutat Res       Date:  2011-08-12       Impact factor: 2.433

5.  DNA repair gene polymorphisms, bulky DNA adducts in white blood cells and bladder cancer in a case-control study.

Authors:  G Matullo; S Guarrera; S Carturan; M Peluso; C Malaveille; L Davico; A Piazza; P Vineis
Journal:  Int J Cancer       Date:  2001-05-15       Impact factor: 7.396

6.  Susceptibility of XPD and RAD51 genetic variants to carcinoma of urinary bladder in North Indian population.

Authors:  Ranbir Chander Sobti; Saranjeet Kaur; Vijay Lakshmi Sharma; Shrawan Kumar Singh; Seyed Ali Hosseini; Rupinder Kler
Journal:  DNA Cell Biol       Date:  2011-07-08       Impact factor: 3.311

Review 7.  ERCC2/XPD gene polymorphisms and cancer risk.

Authors:  Simone Benhamou; Alain Sarasin
Journal:  Mutagenesis       Date:  2002-11       Impact factor: 3.000

8.  TFIIH with inactive XPD helicase functions in transcription initiation but is defective in DNA repair.

Authors:  G S Winkler; S J Araújo; U Fiedler; W Vermeulen; F Coin; J M Egly; J H Hoeijmakers; R D Wood; H T Timmers; G Weeda
Journal:  J Biol Chem       Date:  2000-02-11       Impact factor: 5.157

9.  The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway.

Authors:  X W Wang; W Vermeulen; J D Coursen; M Gibson; S E Lupold; K Forrester; G Xu; L Elmore; H Yeh; J H Hoeijmakers; C C Harris
Journal:  Genes Dev       Date:  1996-05-15       Impact factor: 11.361

10.  Polymorphisms of the DNA gene XPD and risk of bladder cancer in a Southeastern Chinese population.

Authors:  Jianfeng Shao; Min Gu; Zhuoqun Xu; Qiang Hu; Lixin Qian
Journal:  Cancer Genet Cytogenet       Date:  2007-08
View more
  4 in total

1.  Polymorphisms in XRCC1, ERCC2, and ERCC3 DNA repair genes, CYP1A1 xenobiotic metabolism gene, and tobacco are associated with bladder cancer susceptibility in Tunisian population.

Authors:  Molka Feki-Tounsi; Rim Khlifi; Ibtihel Louati; Mohamed Fourati; Mohamed-Nabil Mhiri; Amel Hamza-Chaffai; Ahmed Rebai
Journal:  Environ Sci Pollut Res Int       Date:  2017-08-12       Impact factor: 4.223

2.  Association Between TP53 Gene Codon 72 Polymorphism and Acute Myeloid Leukemia Susceptibility: Evidence Based on a Meta-Analysis.

Authors:  Xiao-Lan Ruan; Sheng Li; Peiliang Geng; Xian-Tao Zeng; Guo-Zheng Yu; Xiang-Yu Meng; Qing-Ping Gao; Xu-Bin Ao
Journal:  Med Sci Monit       Date:  2015-10-09

3.  Bone Morphogenetic Protein-7 Antagonizes Myocardial Fibrosis Induced by Atrial Fibrillation by Restraining Transforming Growth Factor-β (TGF-β)/Smads Signaling.

Authors:  Xinjun Chen; Jing Xu; Baozhou Jiang; Danping Liu
Journal:  Med Sci Monit       Date:  2016-09-28

Review 4.  The Role of TP53 Gene Codon 72 Polymorphism in Leukemia: A PRISMA-Compliant Systematic Review and Meta-Analysis.

Authors:  Xiao-Lan Ruan; Sheng Li; Xiang-Yu Meng; Peiliang Geng; Qing-Ping Gao; Xu-Bin Ao
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.